Furthermore, an increased expression level of inhibitory membrane-bound complement regulatory protein (mCRP) CD59 has been associated with rituximab resistance in chronic lymphocytic leukemia (CLL) patients (35). The gene discussed is CD59; the disease is B-cell chronic lymphocytic leukemia.